Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, today announced that it has entered into definitive agreements with investors to purchase an aggregate of 1,580,000 shares of common stock at a price ...
Tags: Oramed Pharmaceuticals, Aegis Capital, registered direct offering
Israel-based oral drug delivery systems developer Oramed Pharmaceuticals has received two additional patent approvals in Japan and Canada for its platform protein oral delivery (POD) technology. The two patents are entitled 'Methods and ...
Tags: Pod Technology, Oramed
The Russia's Federal Service for Intellectual Property, Patents and Trademarks has issued a patent to Israel-based Oramed Pharmaceuticals related to methods and compositions for oral administration of proteins. The patent titled "Methods ...
Israel-based oral drug delivery systems developer Oramed Pharmaceuticals has received an approval for a patent, titled 'Methods and Compositions for Oral Administrations of Proteins', from the State Intellectual Property Office of the ...
Oral drug delivery systems developer Oramed Pharmaceuticals has submitted a pre-Investigational New Drug (pre-IND) seeking approval from the US Food and Drug Administration (FDA) to commence a trial on its orally ingestible exenatide ...
The US Food and Drug Administration (FDA) has cleared Oramed's investigational new drug (IND) application for ORMD-0801, an oral insulin capsule, allowing the company to begin clinical trials of the drug. ORMD-0801 is an orally ingestible ...
Tags: FDA, Oral Insulin Capsule
Israel-based biotechnology company Oramed Pharmaceuticals has received the patent from the Japanese patent office for its technology in oral delivery of proteins. The patent, titled "Methods and Compositions for Oral Administrations of ...
Tags: Oramed Pharmaceuticals, Oral Delivery Technology, Medicine
Oramed Pharmaceuticals has gained a patent entitled, Methods and Compositions for Oral Administrations of Proteins, from the Israeli Patent Office. The patent covers a central facet of the company's core technology in oral delivery of ...
Tags: Medicine, Oramed Pharmaceuticals, Core Delivery Technology
Oramed, a wholly owned Israeli subsidiary of Oramed Pharmaceuticals, has received government grant of NIS2m (approximately $540,000) in Israel. The funds will be used to support R&D and clinical studies on the company's oral insulin ...
Tags: Oramed Pharmaceuticals, Medicine